Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry

[1]  Myeloid/Lymphoid Neoplasms with Eosinophilia and Rearrangement of PDGFRA, PDGFRB, or FGFR1, or with PCM1-JAK2 , 2020, Definitions.

[2]  M. Triggiani,et al.  The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. , 2019, The journal of allergy and clinical immunology. In practice.

[3]  J. Butterfield,et al.  Mast Cell Mediators of Significance in Clinical Practice in Mastocytosis. , 2018, Immunology and allergy clinics of North America.

[4]  A. Órfão,et al.  Characterization of CD34+ hematopoietic cells in systemic mastocytosis: Potential role in disease dissemination , 2018, Allergy.

[5]  G. Nilsson,et al.  Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. , 2017, Cancer research.

[6]  W. Hofmann,et al.  KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance , 2015, American journal of hematology.

[7]  P. Valent,et al.  Mast Cells, Mastocytosis, and Related Disorders. , 2015, The New England journal of medicine.

[8]  M. Triggiani,et al.  KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis , 2015, Leukemia.

[9]  P. Weller,et al.  Eosinophilia in mast cell disease. , 2014, Immunology and allergy clinics of North America.

[10]  T. Haferlach,et al.  Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. , 2012, The Journal of allergy and clinical immunology.

[11]  Torsten Haferlach,et al.  Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field , 2012, Expert review of hematology.

[12]  H. Kluin-Nelemans,et al.  The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). , 2010, Blood.

[13]  K. Sotlar,et al.  Variable presence of KITD816V in clonal haematological non‐mast cell lineage diseases associated with systemic mastocytosis (SM–AHNMD) , 2010, The Journal of pathology.

[14]  A. Tefferi,et al.  Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. , 2009, Blood.

[15]  R. Yeh,et al.  The molecular anatomy of the FIP1L1-PDGFRA fusion gene , 2009, Leukemia.

[16]  D. Metcalfe.  Mast cells and mastocytosis. , 2008, Blood.

[17]  P. Weller,et al.  Immunoregulatory roles of eosinophils: a new look at a familiar cell , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[18]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[19]  M. Fay,et al.  KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. , 2007, The Journal of allergy and clinical immunology.

[20]  O. Haas,et al.  Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. , 2007, The Journal of allergy and clinical immunology.

[21]  M. Triggiani,et al.  Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria , 2007, European journal of clinical investigation.

[22]  A. Órfão,et al.  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. , 2006, Blood.

[23]  J. Butterfield.  Systemic mastocytosis: clinical manifestations and differential diagnosis. , 2006, Immunology and allergy clinics of North America.

[24]  A. Tefferi,et al.  Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia. , 2003, Leukemia research.

[25]  L. Scott,et al.  Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. , 2000, Experimental hematology.

[26]  D. Metcalfe,et al.  Elevated expression of the proto-oncogene c-kit in patients with mastocytosis , 1998, Leukemia.

[27]  Laura H. Tang,et al.  Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm , 1996, Nature Genetics.

[28]  W. Travis,et al.  Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. , 1991, The American journal of medicine.

[29]  P. Weller,et al.  The immunobiology of eosinophils. , 1991, The New England journal of medicine.

[30]  D. Metcalfe.  The liver, spleen, and lymph nodes in mastocytosis. , 1991, The Journal of investigative dermatology.

[31]  D. Metcalfe,et al.  Classification and diagnosis of mastocytosis: current status. , 1991, The Journal of investigative dermatology.

[32]  E. Bergstralh,et al.  Systemic Mast Cell Disease: ANALYSIS OF 58 CASES AND LITERATURE REVIEW , 1988, Medicine.

[33]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.